CA3267555A1 - Compositions d'analogues de n-n-diméthyltryptamine (dmt) et de dmt, leurs procédés de fabrication et leurs procédés d'utilisation - Google Patents
Compositions d'analogues de n-n-diméthyltryptamine (dmt) et de dmt, leurs procédés de fabrication et leurs procédés d'utilisationInfo
- Publication number
- CA3267555A1 CA3267555A1 CA3267555A CA3267555A CA3267555A1 CA 3267555 A1 CA3267555 A1 CA 3267555A1 CA 3267555 A CA3267555 A CA 3267555A CA 3267555 A CA3267555 A CA 3267555A CA 3267555 A1 CA3267555 A1 CA 3267555A1
- Authority
- CA
- Canada
- Prior art keywords
- dmt
- methods
- dimethyltryptamine
- making
- analog compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/974,443 US20230136824A1 (en) | 2021-04-26 | 2022-10-26 | N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof |
| PCT/US2023/077879 WO2024092106A2 (fr) | 2022-10-26 | 2023-10-26 | Compositions d'analogues de n-n-diméthyltryptamine (dmt) et de dmt, leurs procédés de fabrication et leurs procédés d'utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3267555A1 true CA3267555A1 (fr) | 2024-05-02 |
Family
ID=90832092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3267555A Pending CA3267555A1 (fr) | 2022-10-26 | 2023-10-26 | Compositions d'analogues de n-n-diméthyltryptamine (dmt) et de dmt, leurs procédés de fabrication et leurs procédés d'utilisation |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4608395A2 (fr) |
| AR (1) | AR130877A1 (fr) |
| AU (1) | AU2023367107A1 (fr) |
| CA (1) | CA3267555A1 (fr) |
| TW (1) | TW202423415A (fr) |
| WO (1) | WO2024092106A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3182156A1 (fr) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Nouvelles compositions de matiere et compositions pharmaceutiques |
| EP4347562A4 (fr) | 2021-05-25 | 2025-04-30 | ATAI Therapeutics, Inc. | Nouveaux sels de n,n-diméthyltryptamine et nouvelles formes de sel cristallin |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3146050A1 (fr) * | 2019-07-04 | 2021-01-07 | Sw Holdings, Inc. | Compositions de dosage et procedes d'utilisation de composes psychedeliques |
| US20210015738A1 (en) * | 2019-07-17 | 2021-01-21 | Concept Matrix Solutions | Oral dissolvable film containing psychedelic compound |
| CA3182156A1 (fr) * | 2020-05-08 | 2021-11-11 | Psilera Inc. | Nouvelles compositions de matiere et compositions pharmaceutiques |
| BR112022025306A2 (pt) * | 2020-06-12 | 2023-02-28 | Beckley Psytech Ltd | Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina |
| CA3192617A1 (fr) * | 2020-09-20 | 2022-03-24 | Matthew BAGGOTT | Compositions de tryptamine avantageuses pour troubles mentaux ou amelioration mentale |
| MX2023012651A (es) * | 2021-04-26 | 2023-11-06 | Atai Therapeutics Inc | Novedosas composiciones y metodos de n,n-dimetiltriptamina. |
-
2023
- 2023-10-26 WO PCT/US2023/077879 patent/WO2024092106A2/fr not_active Ceased
- 2023-10-26 EP EP23883743.9A patent/EP4608395A2/fr active Pending
- 2023-10-26 AR ARP230102864A patent/AR130877A1/es unknown
- 2023-10-26 AU AU2023367107A patent/AU2023367107A1/en active Pending
- 2023-10-26 CA CA3267555A patent/CA3267555A1/fr active Pending
- 2023-10-26 TW TW112141056A patent/TW202423415A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR130877A1 (es) | 2025-01-29 |
| AU2023367107A1 (en) | 2025-03-27 |
| WO2024092106A2 (fr) | 2024-05-02 |
| TW202423415A (zh) | 2024-06-16 |
| EP4608395A2 (fr) | 2025-09-03 |
| WO2024092106A3 (fr) | 2024-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3267555A1 (fr) | Compositions d'analogues de n-n-diméthyltryptamine (dmt) et de dmt, leurs procédés de fabrication et leurs procédés d'utilisation | |
| EP3965780A4 (fr) | Compositions oligonucléotidiques et leurs procédés d'utilisation | |
| EP3976638A4 (fr) | Compositions d'il-2 et leurs méthodes d'utilisation | |
| EP4313003A4 (fr) | Compositions de polynucléotides, formulations associées et leurs méthodes d'utilisation | |
| IL299108A (en) | Analogues of hydroxynoractamine, preparations including them and methods of using them | |
| EP4081231A4 (fr) | Compositions comprenant des microbes et leurs procédés d'utilisation et de fabrication | |
| CA3262480A1 (fr) | Compositions ciblant des protéines d'activation des fibroblastes et leurs méthodes d'utilisation | |
| IL308221A (en) | Preparations and methods for treating depression | |
| IL308041A (en) | Collagen compositions and methods of using them | |
| EP4376846A4 (fr) | Compositions bioactives et procédés d'utilisation de celles-ci | |
| IL318328A (en) | Compositions comprising multi-agonist peptides and methods for making and using them | |
| EP4204004A4 (fr) | Compositions anti-idiotype et procédés d'utilisation associés | |
| EP4298076A4 (fr) | Compositions céramiques et leurs procédés d'utilisation | |
| EP4381022A4 (fr) | Compositions et leurs procédés d'utilisation | |
| GB202319843D0 (en) | CAS13-based compositions and methods of use thereof | |
| IL312928A (en) | Complement Factor B Modulating Preparations and Methods for Using Them | |
| CA3259912A1 (fr) | Compositions de tirzepatide et leur utilisation | |
| IL314226A (en) | Designed cytokine compositions and methods of use | |
| IL313980A (en) | The compositions containing the alpha-Factor Perro sequence and uses thereof | |
| IL315862A (en) | Angiotensinogen modulators and methods of using them | |
| CA3257282A1 (fr) | Compositions de collagène et leurs procédés d'utilisation | |
| MX2024000801A (es) | Composiciones para el cuidado oral. | |
| GB202215745D0 (en) | Compositions and methods and uses thereto | |
| IL314293A (en) | Olanzapine, its compounds and methods of using it | |
| IL323920A (en) | MAPT modulators and methods of using them |